ArticleFrontiers in oncology2021

Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment.

Hong-Shuai Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.